- Home
- STG vs BYSI Comparison
STG vs BYSI Comparison
Compare STG & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STG
- BYSI
- Stock Information
- Founded
- STG 2003
- BYSI 2010
- Country
- STG China
- BYSI United States
- Employees
- STG N/A
- BYSI N/A
- Industry
- STG Other Consumer Services
- BYSI Biotechnology: Pharmaceutical Preparations
- Sector
- STG Real Estate
- BYSI Health Care
- Exchange
- STG Nasdaq
- BYSI Nasdaq
- Market Cap
- STG 73.4M
- BYSI 71.0M
- IPO Year
- STG 2018
- BYSI 2017
- Fundamental
- Price
- STG $9.20
- BYSI $2.05
- Analyst Decision
- STG
- BYSI
- Analyst Count
- STG 0
- BYSI 0
- Target Price
- STG N/A
- BYSI N/A
- AVG Volume (30 Days)
- STG 63.0K
- BYSI 24.9K
- Earning Date
- STG 08-14-2025
- BYSI 08-11-2025
- Dividend Yield
- STG N/A
- BYSI N/A
- EPS Growth
- STG N/A
- BYSI N/A
- EPS
- STG 3.09
- BYSI N/A
- Revenue
- STG $269,356,990.00
- BYSI N/A
- Revenue This Year
- STG N/A
- BYSI N/A
- Revenue Next Year
- STG N/A
- BYSI N/A
- P/E Ratio
- STG $3.20
- BYSI N/A
- Revenue Growth
- STG N/A
- BYSI N/A
- 52 Week Low
- STG $4.25
- BYSI $0.98
- 52 Week High
- STG $15.00
- BYSI $3.44
- Technical
- Relative Strength Index (RSI)
- STG 50.13
- BYSI 45.65
- Support Level
- STG $10.08
- BYSI $1.87
- Resistance Level
- STG $11.50
- BYSI $2.13
- Average True Range (ATR)
- STG 1.57
- BYSI 0.15
- MACD
- STG -0.28
- BYSI -0.01
- Stochastic Oscillator
- STG 0.85
- BYSI 46.55
About STG Sunlands Technology Group
Sunlands Technology Group is a provider of online post-secondary and professional education services in China. The company offers various degree- and diploma-oriented post-secondary courses through its online platforms. In addition, it provides online professional courses and educational content to help students prepare for professional certification exams and attain professional skills. The Group has one operating segment, which is the provision of online education services.
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.